Stock AMGN AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Amgen Inc. Buenos Aires S.E.

Equities

AMGN

ARDEUT110665

Pharmaceuticals

End-of-day quote Buenos Aires S.E.
Other stock markets
 23:00:00 21/05/2024 BST 		5-day change 1st Jan Change
12,890 ARS +2.77% Intraday chart for Amgen Inc. +10.48% +38.11%
05-22 Sandoz: Marketing authorization for Wyost and Jubbonti in the EU CF
05-22 Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 143,240 133,852 126,718 140,139 154,142 165,978 - -
Enterprise Value (EV) 1 164,232 156,191 151,990 169,779 207,811 214,434 209,521 204,525
P/E ratio 18.7 x 18.7 x 21.9 x 21.7 x 23.1 x 38.9 x 24.7 x 22.2 x
Yield 2.41% 2.78% 3.13% 2.95% 2.96% 2.98% 3.23% 3.45%
Capitalization / Revenue 6.13 x 5.26 x 4.88 x 5.32 x 5.47 x 5.03 x 4.89 x 4.78 x
EV / Revenue 7.03 x 6.14 x 5.85 x 6.45 x 7.37 x 6.5 x 6.17 x 5.89 x
EV / EBITDA 12.3 x 9.8 x 9.61 x 10.5 x 11.9 x 11.5 x 10.9 x 10.3 x
EV / FCF 19.2 x 15.8 x 18.1 x 19.3 x 28.2 x 14.1 x 16.4 x 15.7 x
FCF Yield 5.2% 6.33% 5.51% 5.17% 3.54% 7.07% 6.09% 6.37%
Price to Book 14.7 x 14.1 x 18.7 x 38.3 x 24.7 x 28.5 x 23.7 x 19.1 x
Nbr of stocks (in thousands) 594,184 582,169 563,266 533,579 535,178 536,435 - -
Reference price 2 241.1 229.9 225.0 262.6 288.0 309.4 309.4 309.4
Announcement Date 30/01/20 02/02/21 07/02/22 31/01/23 06/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 23,362 25,424 25,979 26,323 28,190 33,000 33,964 34,707
EBITDA 1 13,363 15,935 15,822 16,178 17,470 18,705 19,196 19,808
EBIT 1 11,157 12,334 12,424 12,761 13,399 14,790 15,514 15,989
Operating Margin 47.76% 48.51% 47.82% 48.48% 47.53% 44.82% 45.68% 46.07%
Earnings before Tax (EBT) 1 9,138 8,133 6,701 7,346 7,855 4,604 8,649 8,101
Net income 1 7,842 7,264 5,893 6,552 6,717 4,133 6,611 7,022
Net margin 33.57% 28.57% 22.68% 24.89% 23.83% 12.52% 19.46% 20.23%
EPS 2 12.88 12.31 10.28 12.11 12.49 7.952 12.53 13.94
Free Cash Flow 1 8,532 9,889 8,381 8,785 7,359 15,165 12,760 13,033
FCF margin 36.52% 38.9% 32.26% 33.37% 26.11% 45.95% 37.57% 37.55%
FCF Conversion (EBITDA) 63.85% 62.06% 52.97% 54.3% 42.12% 81.07% 66.47% 65.8%
FCF Conversion (Net income) 108.8% 136.14% 142.22% 134.08% 109.56% 366.94% 193.02% 185.62%
Dividend per Share 2 5.800 6.400 7.040 7.760 8.520 9.235 9.988 10.67
Announcement Date 30/01/20 02/02/21 07/02/22 31/01/23 06/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 6,846 6,238 6,594 6,652 6,839 6,105 6,986 6,903 8,196 7,447 8,321 8,434 8,808 8,099 8,592
EBITDA 1 3,849 3,981 4,163 4,114 3,920 3,721 4,411 4,298 5,040 4,477 5,147 5,302 5,053 - -
EBIT 1 2,997 3,140 3,335 3,277 3,009 2,821 3,515 3,403 3,660 3,078 3,790 3,910 4,019 3,657 3,975
Operating Margin 43.78% 50.34% 50.58% 49.26% 44% 46.21% 50.31% 49.3% 44.66% 41.33% 45.55% 46.35% 45.62% 45.16% 46.27%
Earnings before Tax (EBT) 1 2,131 1,675 1,531 2,392 1,748 3,442 1,614 1,947 852 -68 1,558 1,584 1,538 2,599 2,985
Net income 1 1,899 1,476 1,317 2,143 1,616 2,841 1,379 1,730 767 -113 1,263 1,287 1,154 1,663 1,996
Net margin 27.74% 23.66% 19.97% 32.22% 23.63% 46.54% 19.74% 25.06% 9.36% -1.52% 15.18% 15.27% 13.1% 20.53% 23.23%
EPS 2 3.360 2.680 2.450 3.980 3.000 5.280 2.570 3.220 1.420 -0.2100 2.500 2.739 2.503 3.105 3.740
Dividend per Share 2 1.760 1.940 1.940 1.940 1.940 2.130 2.130 2.130 2.130 2.250 2.305 2.305 2.305 2.580 2.580
Announcement Date 07/02/22 27/04/22 04/08/22 03/11/22 31/01/23 27/04/23 03/08/23 31/10/23 06/02/24 02/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 20,992 22,339 25,272 29,640 53,669 48,456 43,543 38,547
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.571 x 1.402 x 1.597 x 1.832 x 3.072 x 2.591 x 2.268 x 1.946 x
Free Cash Flow 1 8,532 9,889 8,381 8,785 7,359 15,165 12,760 13,033
ROE (net income / shareholders' equity) 81.4% 103% 122% 185% 203% 156% 156% 153%
ROA (Net income/ Total Assets) 14.3% 16% 15.8% 15.2% 12.4% 6.32% 7.8% 9.12%
Assets 1 54,778 45,481 37,328 43,230 54,315 65,384 84,801 76,990
Book Value Per Share 2 16.40 16.30 12.00 6.860 11.60 10.90 13.10 16.20
Cash Flow per Share 2 15.00 17.80 16.20 18.00 15.70 20.70 21.30 25.30
Capex 1 618 608 880 936 1,112 1,069 1,047 1,160
Capex / Sales 2.65% 2.39% 3.39% 3.56% 3.94% 3.24% 3.08% 3.34%
Announcement Date 30/01/20 02/02/21 07/02/22 31/01/23 06/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Amgen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.4 USD
Average target price
316.1 USD
Spread / Average Target
+2.15%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.21% 723B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.28% 595B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.70% 369B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.37% 332B
ABBVIE INC. Stock AbbVie Inc.
+2.92% 282B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 244B
NOVARTIS AG Stock Novartis AG
+9.31% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-5.07% 205B
PFIZER, INC. Stock Pfizer, Inc.
+0.09% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. AMGN Stock
  5. Financials Amgen Inc.